Safety of Frontline Durvalumab Combo Confirmed in Extensive-Stage Small Cell Lung Cancer

Virginia Powers, PhD
Published: Friday, Jan 03, 2020
Mustafa Ozguroglu, MD

Mustafa Ozguroglu, MD

Few immune-mediated adverse events (imAEs) were observed with frontline durvalumab (Imfinzi) plus platinum-based therapy and etoposide in patients with extensive-stage small cell lung cancer (ES-SCLC), and no treatment-emergent antidrug antibodies were elicited by the PD-L1 inhibitor, according to an analysis of the phase III CASPIAN trial reported at the 2019 ESMO Immuno-Oncology Congress.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication